The Role of Complement in Cerebrospinal Fluid Shunt Infections
补体在脑脊液分流感染中的作用
基本信息
- 批准号:9976246
- 负责人:
- 金额:$ 19.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAgeAlzheimer&aposs DiseaseAnimal ModelAntibiotic TherapyAstrocytesAwardBacteriaBacterial MeningitisBrainCathetersCerebral EdemaCerebrospinal fluid shunts procedureChildChildhoodChronicClinicalClinical MedicineCommunicable DiseasesComplementComplement 1qComplement ActivationComplement InactivatorsComplicationDataDevelopmentDevelopment PlansDiseaseEffector CellEtiologyFoundationsFutureGoalsHemorrhageHomeostasisHumanHydrocephalusImmuneInfectionInflammatoryIntracranial HypertensionIntrathecal SpaceKineticsKnock-outKnockout MiceKnowledgeLeadLectinLoxP-flanked alleleMediatingMicrogliaMolecularMultiple SclerosisMusNerve DegenerationNervous System TraumaNeuraxisNeurologicNeurologic DeficitNeurosurgeonOutcomePathologicPathologyPathway interactionsPatient-Focused OutcomesPatientsPerformancePhysiciansProceduresRiskRisk FactorsRoleSchoolsScientistSeizuresShunt DeviceSourceSpecialistStaphylococcus epidermidisStrokeSystemTechnical ExpertiseTestingTimeTrainingTraumatic Brain InjuryUnited Statesadverse outcomeanimal tissuebasebrain tissuecareer developmentcomplement C3 precursorcomplement pathwayconditional knockoutexperienceexperimental studyhigh riskimprovedknockout animalknowledge basemacrophagemortalitymouse modelnervous system disorderneuron lossnew therapeutic targetnovel strategiesnovel therapeuticspathogenpediatric patientsprematureresponseretinogeniculatesynaptic pruningtherapeutic target
项目摘要
PROJECT SUMMARY
Cerebrospinal fluid shunt infections are a frequent and serious complication of the treatment of hydrocephalus,
occurring in 5-30% of patients1, 2. These infections are associated with significant long-term neurologic
sequelae such as lower IQ, poor school performance and increased risk of seizures 9-13. The mechanisms
responsible for the severe neurologic damage associated with shunt infection are unknown.
Studies have demonstrated the role of complement in normal neurologic development through developmentally
appropriate complement mediated synaptic pruning by microglia 19,20,22. Additional studies have revealed the
role of complement in a variety of neurologic disorders and infection supporting a central role for complement
in central nervous system homeostasis and pathology24-33. My preliminary studies in an animal model of shunt
infection have demonstrated elevated levels of the complement components C3 and C5 in brain tissue at day 5
and 10 when bacterial burdens are low, suggesting complement may mediate the neurologic damage
associated with shunt infections. This is further supported by my preliminary data demonstrating that synaptic
pruning is less dramatic in C3 knockout mice. The overall objective of this proposal is to understand the role of
complement in a murine model of CNS catheter infection, to facilitate the future identification of novel
therapeutic targets to limit neurologic damage in pediatric patients. Understanding the mechanisms
whereby complement mediates neurologic damage would allow us to take advantage of many
complement inhibitors that are being developed for clinical medicine as potential adjuvants to
antibiotic therapy to improve long-term patient outcomes 35,36.
Our central hypothesis is that complement components induce microglial-mediated synaptic pruning and are
responsible for late-stage cerebral edema. To test this hypothesis, we will perform experiments outlined in two
specific aims. In Aim 1, we will identify the primary mode of complement pathway activation during CNS S.
epidermidis catheter-associated infection and functional importance. In Aim 2, we will define the molecular
mechanisms of complement-mediated damage during CNS catheter infection.
Finally, the candidate is a pediatric infectious disease specialist with a long-standing experience investigating
shunt infections. She is a well-supported candidate with the goal of becoming a physician scientist and would
highly benefit from a Clinical Scientist Development Award.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gwenn L Skar其他文献
Gwenn L Skar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gwenn L Skar', 18)}}的其他基金
The Role of Complement in Cerebrospinal Fluid Shunt Infections
补体在脑脊液分流感染中的作用
- 批准号:
10395980 - 财政年份:2020
- 资助金额:
$ 19.21万 - 项目类别:
The Role of Complement in Cerebrospinal Fluid Shunt Infections
补体在脑脊液分流感染中的作用
- 批准号:
10599224 - 财政年份:2020
- 资助金额:
$ 19.21万 - 项目类别:
相似海外基金
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10458553 - 财政年份:2021
- 资助金额:
$ 19.21万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10220588 - 财政年份:2021
- 资助金额:
$ 19.21万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10620718 - 财政年份:2021
- 资助金额:
$ 19.21万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10415762 - 财政年份:2021
- 资助金额:
$ 19.21万 - 项目类别:
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo
剖析年龄特异性佐剂体外和体内协同作用的机制
- 批准号:
9108575 - 财政年份:2016
- 资助金额:
$ 19.21万 - 项目类别:
CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older - LC 3
CoVPN 3005:两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性 - LC 3
- 批准号:
10570739 - 财政年份:2006
- 资助金额:
$ 19.21万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10686595 - 财政年份:2006
- 资助金额:
$ 19.21万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - 两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成年人的功效、免疫原性和安全性
- 批准号:
10581414 - 财政年份:2006
- 资助金额:
$ 19.21万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10579557 - 财政年份:2006
- 资助金额:
$ 19.21万 - 项目类别: